In October 2021, the world's first malaria vaccine RTS, S was endorsed by WHO for broad
use in children, despite its low efficacy. This study examined polyclonal infections and the …

Abstract Background In 2021 and 2023, the World Health Organization approved RTS,
S/AS01 and R21/Matrix M malaria vaccines, respectively, for routine immunization of …

Background Extensive genetic diversity in the Plasmodium falciparum circumsporozoite
protein (PfCSP) is a major contributing factor to the moderate efficacy of the RTS, S/AS01 …

Background The currently used malaria vaccine, RTS, S, is designed based on the
Plasmodium falciparum circumsporozoite protein (PfCSP). The pfcsp gene, besides having …

The malaria vaccine candidate RTS, S/AS01 is based on immunogenic regions of
Plasmodium falciparum circumsporozoite protein (CSP) from the 3D7 reference strain and …

The Plasmodium falciparum Circumsporozoite Protein (PfCSP) has been used in
developing the RTS, S, and R21 malaria vaccines. However, genetic polymorphisms within …

Abstract The RTS, S/AS01 malaria vaccine encompasses the central repeats and C-terminal
of Plasmodium falciparum circumsporozoite protein (PfCSP). Although no Phase II clinical …

Abstract Background Malaria caused by Plasmodium falciparum parasite is still known to be
one of the most significant public health problems in sub-Saharan Africa. Genetic diversity of …

RTS, S is the most advanced malaria vaccine candidate, currently under phase-III clinical
trials in Africa. This Plasmodium falciparum vaccine contains part of the central repeat region …

Background Plasmodium falciparum circumsporozoite protein (PfCSP) is a potential malaria
vaccine candidate, but various polymorphisms of the pfcsp gene among global P. falciparum …